Platform & Pipeline


151810679 Vigil® is a fully personalized, patient-specific cancer immunotherapy that can be applied to virtually any cancer from which a surgical sample can be gathered.To date, we have conducted a Phase 1 study identifying the clinical dose and establishing the early safety profile for the platform. The tumor types studied in Phase 1 included, but not limited to:
  • Ovarian cancer
  • Breast cancer
  • Melanoma
  • Ewing’s Sarcoma
  • Non-small cell lung cancer
  • Colon cancer
  • Hepatocellular cancer
Our lead program focuses on the treatment of patients with recurrent or refractory Ewing’s Sarcoma.  Vigil® utilizes the patient’s own cancer cells to create a fully personalized cancer immunotherapy with the goal to activate the patient’s own T cells against their cancer cells.  We believe Vigil® has several key features and advantages which differentiate it from other cancer immunotherapies:
  1. We use the entire compliment of antigens present in patient’s cancer cells by using surgically removed tumor tissue. The goal is to stimulate a robust immune response (T-cell activation) against a heterogeneous mix of cancer neoantigens specific to that patient.
  2. With gene modification, we specifically down-regulate an immunosuppressive pathway of the cancer cells; and at the same time, up-regulate an immune stimulation function of those same cells.

When those cells are reintroduced back into the patient, these two modifications are designed to help activate the immune system to detect and kill any cancer cells that may remain locally and in circulation.  All together, the goal is to stimulate the existing components of the immune system with the intent to improve their antitumor responses. We simply enhance specific functions that assist in cancer antigen recognition and dampen other functions that cancer cells often employ to evade the immune system.

We believe our approach of exploiting the existing, highly-adapted immune system by presenting the entire neoantigen matrix and induced T-cell responses against their cancer has great promise.